Health News | Research Suggests That Low Doses of Mushrooms May Be Beneficial for Mental Diseases

Washington DC [US], October 7 (ANI): According to a recent study from the University of Southern Denmark, psilocybin, the primary component of psychedelic mushrooms, may be administered in small doses to treat various medical conditions.

Long recognised as a traditional psychedelic chemical, psilocybin is now being researched for its potential to help cure a variety of psychiatric conditions, particularly addiction and depression, through therapy combined with a high dose of psilocybin.

Also Read | World Mental Health Day 2023: 90% Indians Blame Fast-Paced Lifestyle for Growing Mental Health Issues, Says Survey.

In such therapeutic treatment, the patient takes psilocybin after thorough therapeutic preparation and undergoes a psychedelic experience in a supportive environment with a trained therapist. Subsequently, the experience is integrated over several therapy sessions.

Experiments are being conducted with patients at hospitals, including Bispebjerg Hospital and Rigshospitalet.

Also Read | Breast Cancer Awareness Month 2023: Easy Steps For a Breast Self-Exam at Home.

Microdosing in Rats

In the recent study published in Nature - Molecular Psychiatry, Associate Professor Mikael Palner and PhD student Kat Kiilerich from the Research Unit for Clinical Physiology and Nuclear Medicine at the University of Southern Denmark examined the effects of small doses of psilocybin on rats.

Their focus was on repeated low doses of psilocybin, which are significantly lower than the doses typically used in therapeutic settings and are commonly referred to as 'microdosing.'

Microdosing is a phenomenon popularized within performance culture, notably in areas like Silicon Valley, California, and has subsequently spread through stories and anecdotes on the internet as a form of self-medication for various challenges, explains Mikael Palner, the last author of the study.

Effective for Stress and Compulsive Behaviors

The study conducted on rats showed that animals tolerated the repeated low doses of psilocybin well and did not exhibit signs of reduced pleasure (anhedonia), anxiety, or altered locomotor activity.

Most notably, repeated low doses of psilocybin increased the rats' resilience to stress, and they displayed fewer compulsive behaviours.

Additionally, an increase in the number of connections to the thalamus region of the brain, which serves as a kind of filter for our decisions and concerns, was observed.

The change in connectivity to the thalamus may contribute to our enhanced resilience to stress factors and could explain why so many people report positive effects on their well-being from small doses of psychedelic mushrooms.

A Promising New Approach

Through the new study, the researchers have established a valid method that can be utilized for further research into the effects of repeated low doses of psilocybin. The study also lends support to the numerous anecdotal reports of the benefits of microdosing as a therapeutic intervention.

This paves the way for additional research and potentially entirely new approaches to treating various mental disorders.

The increased anxiety and stress in society currently have placed a strong focus on microdosing, leading to a surge in the trade of mushrooms. Countries such as the Netherlands, Australia, the USA, and Canada have either legalized or are in the process of legalizing psilocybin for therapeutic treatment, says Mikael Palner.

It is, therefore, crucial that we understand the effects and side effects of these substances, which are already widely used by people around the world.

Enhanced Understanding with Potential

Mikael Palner developed an interest in researching psychedelic substances and psilocybin when he lived in Silicon Valley, California, eleven years ago and witnessed the surge of self-improvement practices that garnered significant media attention and prompted more people to experiment with microdosing.

Some books were published that popularized the concept of using small doses of psychedelics to address both mental issues and enhance performance. This motivated me to launch the project I've been devoted to for the past six years, says Mikael Palner.

Now, we can determine the appropriate dosage in rats, enabling us to investigate the effects of microdosing, which could significantly advance our understanding of the brain and mental challenges. This benefits both the field of science and society at large. (ANI)

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)